Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 01, 2015 4:11 AM ET

Pharmaceuticals

Company Overview of Par Pharmaceutical Companies Inc.

Company Overview

Par Pharmaceutical Companies, Inc. develops, licenses, manufactures, markets, and distributes generic drugs in the United States. It operates through two segments, Par Pharmaceutical and Par Specialty Pharmaceuticals. The Par Pharmaceutical segment markets generic products under Par Pharmaceutical brand name and sterile products under the Par Sterile brand. This segment also offers dosage forms and delivery systems, including oral solids and alternate dosage forms, such as oral solids, injectables, topicals, nasal sprays, ophthalmics, films, and transdermal patches. In addition, this segment markets pharmaceutical products, including Exforge, Lovaza, Precedex, Lamictal XR, Luvox CR, and Foca...

One Ram Ridge Road

Chestnut Ridge, NY 10977

United States

Founded in 1978

1,600 Employees

Phone:

845-573-5500

Key Executives for Par Pharmaceutical Companies Inc.

Chief Executive Officer, Director and Chief Executive Officer of Sky Growth Holdings Corporation
Age: 53
Chief Financial Officer, Executive Vice President, Treasurer and Director
Age: 57
Chief Operating Officer
Age: 49
Chief Commercial Officer
Age: 58
Secretary and Deputy General Counsel
Compensation as of Fiscal Year 2015.

Par Pharmaceutical Companies Inc. Key Developments

Par Pharmaceutical Begins Shipment of Generic Megace® ES

Par Pharmaceutical Companies Inc. announced that it has begun shipping the authorized generic version of Par Specialty Pharmaceutical's Megace® ES (megestrol acetate, USP) oral suspension. Par's launch of its authorized generic product follows a competitor's introduction of the first generic version of Megace® ES. Megace® ES oral suspension is a progestin indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). The product is available in 150 mL bottles.

Par Pharmaceutical Companies Inc., Q1 2015 Fixed Income Call, May 13, 2015

Par Pharmaceutical Companies Inc., Q1 2015 Fixed Income Call, May 13, 2015

Par Pharmaceutical Companies Inc., Q4 2014 Earnings Call, Mar 13, 2015

Par Pharmaceutical Companies Inc., Q4 2014 Earnings Call, Mar 13, 2015

Similar Private Companies By Industry

Company Name Region
Alternecare Health Products, Inc. United States
Research Services Inc. United States
Locus Pharmaceuticals, Inc. United States
Sequel Pharmaceuticals, Inc. United States
Voyager Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 8, 2014
Par Pharmaceuticals, Inc., Three Soft Gel ANDA Products
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Par Pharmaceutical Companies Inc., please visit www.parpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.